| Year |
Citation |
Score |
| 2024 |
Tian T, Aaron RE, DuNova AY, Jendle JH, Kerr D, Cengiz E, Drincic A, Pickup JC, Chen KY, Schwartz N, Muchmore DB, Akturk HK, Levy CJ, Schmidt S, Bellazzi R, et al. Diabetes Technology Meeting 2023. Journal of Diabetes Science and Technology. 19322968241235205. PMID 38528741 DOI: 10.1177/19322968241235205 |
0.382 |
|
| 2023 |
Aaron RE, Tian T, Yeung AM, Huang J, Arreaza-Rubín GA, Ginsberg BH, Kompala T, Lee WA, Kerr D, Colmegna P, Mendez CE, Muchmore DB, Wallia A, Klonoff DC. NIH Fifth Artificial Pancreas Workshop 2023: Meeting Report: The Fifth Artificial Pancreas Workshop: Enabling Fully Automation, Access, and Adoption. Journal of Diabetes Science and Technology. 19322968231201829. PMID 37811866 DOI: 10.1177/19322968231201829 |
0.385 |
|
| 2022 |
Kastner JR, Bailey TS, Strange P, Shi L, Oberg KA, Strasma P, Joseph JI, Muchmore DB. PROGRESSIVE ACCELERATION OF INSULIN EXPOSURE OVER SEVEN DAYS OF INFUSION SET WEAR. Diabetes Technology & Therapeutics. PMID 36342853 DOI: 10.1089/dia.2022.0323 |
0.418 |
|
| 2022 |
Muchmore DB. Regarding: Insulin Infusion Set Failures. Diabetes Technology & Therapeutics. 24: 599-600. PMID 35913844 DOI: 10.1089/dia.2022.0072 |
0.48 |
|
| 2022 |
Weinstock RS, Bode BW, Garg SK, Klonoff DC, El Sanadi C, Geho WB, Muchmore DB, Penn MS. Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes, Obesity & Metabolism. PMID 35546449 DOI: 10.1111/dom.14761 |
0.521 |
|
| 2022 |
Kastner JR, Venkatesh N, Brown K, Muchmore DB, Ekinci E, Fourlanos S, Joseph JI, Shafeeq M, Shi L, Strange P, Strasma PJ, O'Neal DN. Feasibility study of a prototype extended-wear insulin infusion set in adults with type 1 diabetes. Diabetes, Obesity & Metabolism. PMID 35257468 DOI: 10.1111/dom.14685 |
0.446 |
|
| 2020 |
Bode BW, Weinstock RS, Garg SK, Klonoff DC, Singh KK, Muchmore DB, Penn MS, Geho W, Sanadi CEE. 111-LB: Hepatic Insulin Delivery to Minimize Hypoglycemic Events in Persons with Type 1 Diabetes: The OPTI-1 Study Diabetes. 69. DOI: 10.2337/Db20-111-Lb |
0.501 |
|
| 2019 |
Klonoff D, Bode B, Cohen N, Penn M, Geho WB, Muchmore DB. Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes. Diabetes Care. PMID 31551249 DOI: 10.2337/dc19-0152 |
0.61 |
|
| 2019 |
Klonoff DC, Bode BW, Cohen NJ, Geho W, Muchmore DB. 1084-P: Divergent Hypoglycemic Effects of Hepatic Directed Prandial Insulin: A 6-Month Study in Type 1 Diabetes Mellitus (T1DM) Diabetes. 68. DOI: 10.2337/Db19-1084-P |
0.496 |
|
| 2018 |
Pettis RJ, Muchmore D, Heinemann L. Subcutaneous Insulin Administration: Sufficient Progress or Ongoing Need? Journal of Diabetes Science and Technology. 13: 3-7. PMID 30522334 DOI: 10.1177/1932296818817011 |
0.577 |
|
| 2018 |
Muchmore DB. Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them? Journal of Diabetes Science and Technology. 12: 152-154. PMID 29291651 DOI: 10.1177/1932296817750166 |
0.601 |
|
| 2017 |
Muchmore DB. The Need for Faster Insulin. Journal of Diabetes Science and Technology. 11: 157-159. PMID 28264172 DOI: 10.1177/1932296816677577 |
0.626 |
|
| 2017 |
Heinemann L, Muchmore D. Coverage of Prandial Insulin Requirements: An Elusive Goal. Diabetes Technology & Therapeutics. 19: 7-8. PMID 28055259 DOI: 10.1089/dia.2016.0449 |
0.567 |
|
| 2017 |
Klonoff DC, Fleming GA, Muchmore DB, Frier BM. Hypoglycemia Evaluation and Reporting in Diabetes: Importance for the Development of New Therapies. Diabetes/Metabolism Research and Reviews. PMID 28054743 DOI: 10.1002/dmrr.2883 |
0.376 |
|
| 2014 |
Garg SK, Buse JB, Skyler JS, Vaughn DE, Muchmore DB. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes. Diabetes, Obesity & Metabolism. 16: 1065-9. PMID 24840317 DOI: 10.1111/dom.12315 |
0.614 |
|
| 2013 |
Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care. 36: 273-5. PMID 23043164 DOI: 10.2337/dc12-0808 |
0.569 |
|
| 2012 |
Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. Journal of Diabetes Science and Technology. 6: 764-72. PMID 22920800 DOI: 10.1177/193229681200600405 |
0.627 |
|
| 2012 |
Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. Journal of Diabetes Science and Technology. 6: 728-42. PMID 22920797 DOI: 10.1177/193229681200600402 |
0.615 |
|
| 2012 |
Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technology & Therapeutics. 14: 218-24. PMID 22136324 DOI: 10.1089/dia.2011.0117 |
0.485 |
|
| 2011 |
Vaughn DE, Muchmore DB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 17: 914-21. PMID 22138081 DOI: 10.4158/EP11297.RA |
0.487 |
|
| 2011 |
Muchmore D. The End Point is Just the Beginning Journal of Diabetes Science and Technology. 5: 1287-1289. PMID 22027330 DOI: 10.1177/193229681100500538 |
0.324 |
|
| 2011 |
Muchmore D, Sharp M, Vaughn D. Benefits of blinded continuous glucose monitoring during a randomized clinical trial. Journal of Diabetes Science and Technology. 5: 676-80. PMID 21722582 DOI: 10.1177/193229681100500321 |
0.45 |
|
| 2011 |
Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technology & Therapeutics. 13: 1039-45. PMID 21714645 DOI: 10.1089/dia.2011.0115 |
0.48 |
|
| 2011 |
Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care. 34: 666-8. PMID 21273493 DOI: 10.2337/dc10-1892 |
0.569 |
|
| 2010 |
Muchmore DB, Vaughn DE. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. Journal of Diabetes Science and Technology. 4: 419-28. PMID 20307403 DOI: 10.1177/193229681000400223 |
0.643 |
|
| 2009 |
de la Peña A, Seger M, Rave K, Heinemann L, Silverman B, Muchmore DB. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. Diabetes Technology & Therapeutics. 11: S75-80. PMID 19772452 DOI: 10.1089/dia.2009.0057 |
0.44 |
|
| 2009 |
Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Hayes RP, Belin RM. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. Diabetes Technology & Therapeutics. 11: S63-73. PMID 19772451 DOI: 10.1089/dia.2009.0059 |
0.596 |
|
| 2009 |
Bergenstal RM, Freemantle N, Leyk M, Cutler GB, Hayes RP, Muchmore DB. Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes? Diabetes Technology & Therapeutics. 11: S45-52. PMID 19772448 DOI: 10.1089/dia.2009.0028 |
0.502 |
|
| 2009 |
Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technology & Therapeutics. 11: 345-52. PMID 19459762 DOI: 10.1089/dia.2009.0013 |
0.535 |
|
| 2009 |
Vaughn D, Muchmore D, Gee L, Ludington E. Dose response of recombinant human hyaluronidase effects on pharmacokinetics of regular human insulin and insulin lispro following sc injection Canadian Journal of Diabetes. 33: 262. DOI: 10.1016/S1499-2671(09)33198-6 |
0.569 |
|
| 2008 |
Wolzt M, de la Peña A, Berclaz PY, Tibaldi FS, Gates JR, Muchmore DB. AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Diabetes Care. 31: 735-40. PMID 18192544 DOI: 10.2337/dc07-0873 |
0.515 |
|
| 2008 |
Gern JE, Stone CK, Nakano M, Muchmore DB, de la Peña A, Park S, Suri A, Tibaldi F, Soon D, Busse WW. Effect of upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and glucodynamics in healthy subjects. Clinical Pharmacology and Therapeutics. 83: 307-11. PMID 17625517 DOI: 10.1038/sj.clpt.6100286 |
0.552 |
|
| 2007 |
Silverman BL, Barnes CJ, Campaigne BN, Muchmore DB. Inhaled insulin for controlling blood glucose in patients with diabetes. Vascular Health and Risk Management. 3: 947-58. PMID 18200813 |
0.469 |
|
| 2007 |
Rosenstock J, Muchmore D, Swanson D, Schmitke J. AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. Expert Review of Medical Devices. 4: 683-92. PMID 17850203 DOI: 10.1586/17434440.4.5.683 |
0.588 |
|
| 2007 |
Muchmore DB, Silverman B, De La Peña A, Tobian J. The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technology & Therapeutics. 9: S41-7. PMID 17563303 DOI: 10.1089/dia.2007.0218 |
0.472 |
|
| 2007 |
Rave K, de la Peña A, Tibaldi FS, Zhang L, Silverman B, Hausmann M, Heinemann L, Muchmore DB. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care. 30: 1777-82. PMID 17456839 DOI: 10.2337/dc06-2284 |
0.35 |
|
| 2007 |
Hayes RP, Nakano M, Muchmore D, Schmitke J. Effect of standard (self-directed) training versus intensive training for Lilly/Alkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the system Diabetes Technology and Therapeutics. 9: 89-98. PMID 17316103 DOI: 10.1089/dia.2006.0043 |
0.394 |
|
| 2007 |
Rosenstock J, Nakano M, Silverman BL, Sun B, de la Peña A, Suri A, Muchmore DB. Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures. Diabetes Technology & Therapeutics. 9: 80-8. PMID 17316102 DOI: 10.1089/dia.2006.0042 |
0.328 |
|
| 2007 |
Hayes RP, Muchmore D, Schmitke J. Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes Current Medical Research and Opinion. 23: 435-442. PMID 17288697 DOI: 10.1185/030079906X167381 |
0.597 |
|
| 2006 |
Muchmore DB, Gates JR. Inhaled insulin delivery--where are we now? Diabetes, Obesity & Metabolism. 8: 634-42. PMID 17026487 DOI: 10.1111/j.1463-1326.2006.00585.x |
0.557 |
|
| 2006 |
Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peña A, Muchmore DB. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia. 49: 891-9. PMID 16506054 DOI: 10.1007/s00125-006-0161-3 |
0.627 |
|
| 2006 |
Rave K, Nosek L, de la Pena A, Seger M, Ernest II C, Heinemann L, Batycky R, Muchmore D. Dosis-Wirkungsbeziehung von inhalativem Humaninsulin als Pulver (HIIP) und Dosisäquivalenz im Vergleich zu subkutanem Insulin Lispro Diabetologie Und Stoffwechsel. 1. DOI: 10.1055/s-2006-943910 |
0.521 |
|
| 2005 |
Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS, Heinemann L, Batycky RP, Muchmore DB. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care. 28: 2400-5. PMID 16186270 DOI: 10.2337/diacare.28.10.2400 |
0.49 |
|
| 1982 |
Muchmore DB, Raess BU, Bergstrom RW, de Haën C. On the mechanisms of inhibition of insulin action by small-molecular-weight trypsin inhibitors. Diabetes. 31: 976-84. PMID 6757016 |
0.336 |
|
| 1980 |
Muchmore DB, De Haen C. Counterregulatory control of intracellular H2O2 production by insulin and lipolytic hormones in adipocytes Clinical Research. 28: 52A. |
0.46 |
|
| 1979 |
Muchmore DB, De Haen C. Oxytocin stimulation of intracellular hydrogen peroxide production and its relevance to the mechanism of action of insulin in rat adipocytes Clinical Research. 27: 488A. |
0.361 |
|
| Show low-probability matches. |